Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

Core Viewpoint - Spyre Therapeutics, Inc. has announced the pricing of its public offering of 14,864,865 shares at $18.50 per share, aiming to raise approximately $275.0 million in gross proceeds before expenses [1][2]. Company Overview - Spyre Therapeutics is a clinical-stage biotechnology company focused on developing advanced treatments for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases through innovative antibody engineering and therapeutic combinations [5]. Offering Details - The public offering is expected to close around October 15, 2025, pending customary closing conditions [2]. - The underwriters have an option to purchase an additional 2,229,729 shares at the public offering price [1]. - Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated are the joint book-running managers for the offering [2]. Regulatory Information - A registration statement related to the offering has been filed with the SEC and became effective on March 7, 2025 [3]. - The offering will be conducted through a prospectus supplement and accompanying prospectus [3].